Table 1. Patient demographics (N = 555).
| Characteristics | CCRT | Chemotherapy | RT alone | P-value |
|---|---|---|---|---|
| No. | n = 172 | n = 223 | n = 160 | |
| Year | 0.36 | |||
| 2004 | 27 (15.7%) | 30 (13.5%) | 33 (20.6%) | |
| 2005 | 26 (15.1%) | 44 (19.7%) | 28 (17.5%) | |
| 2006 | 39 (22.7%) | 40 (17.9%) | 28 (17.5%) | |
| 2007 | 48 (27.9%) | 57 (25.6%) | 33 (20.6%) | |
| 2008 | 32 (18.6%) | 52 (23.3%) | 38 (23.8%) | |
| Age (mean ±SD) | 46.0 (±10.9) | 45.3 (± 11.0) | 47.5 (± 12.8) | 0.18 |
| Stage | 0.32 | |||
| IB1 | 130 (75.6%) | 181 (81.2%) | 130 (81.3%) | |
| IB2 | 42 (24.4%) | 42 (18.8%) | 30 (18.8%) | |
| Histology | < 0.001 | |||
| Squamous | 130 (75.6%) | 105 (47.1%) | 119 (74.4%) | |
| Adenocarcinoma | 33 (19.2%) | 79 (35.4%) | 25 (15.6%) | |
| Adenosquamous | 9 (5.2%) | 39 (17.5%) | 16 (10.0%) | |
| Deep stromal invasion | 0.02 | |||
| No | 439 (22.7%) | 879 (35.4%) | 45 (28.1%) | |
| Yes | 133 (77.3%) | 144 (64.6%) | 115 (71.9%) | |
| Tumor size | 0.13 | |||
| ≤ 4.0 cm | 125 (72.7%) | 181 (81.2%) | 124 (77.5%) | |
| > 4.0 cm | 47 (27.3%) | 42 (18.8%) | 36 (22.5%) | |
| LVSI | 0.75 | |||
| Not present | 37 (21.5%) | 55 (24.7%) | 36 (22.5%) | |
| Present | 135 (78.5%) | 1768 (75.3%) | 124 (77.5%) | |
| Sampled lymph nodes | ||||
| Pelvic (median IQR) | 26 (16) | 31 (20) | 30 (18) | 0.001 |
| Para-aortic (median IQR)* | 7 (8) | 8 (9) | 5 (7) | 0.045 |
| Risk factor patterns | 0.09 | |||
| Deep stroma alone | 25 (14.5%) | 35 (15.7%) | 25 (15.6%) | |
| Size alone | 2 (1.2%) | 7 (3.1%) | 4 (2.5%) | |
| LVSI alone | 28 (16.3%) | 67 (30.0%) | 36 (22.5%) | |
| Deep stroma + size | 10 (5.8%) | 13 (5.8%) | 7 (4.4%) | |
| LVSI + deep stroma | 72 (41.9%) | 79 (35.4%) | 63 (39.4%) | |
| LVSI+ size | 9 (5.2%) | 5 (2.2%) | 5 (3.1%) | |
| All 3 factors | 26 (15.1%) | 17 (7.6%) | 20 (12.5%) |
Mean (± SD), median (interquartile range), or number (%) per column are shown. One-way ANOVA test, chi-square test, or Kruskal-Wallis H test for P-values. *Performed in 15 cases in CCRT group, 34 cases in chemotherapy group, and 30 cases for RT group, respectively. Abbreviations: IQR, interquartile range; CCRT, concurrent chemoradiotherapy; and LVSI, lympho-vascular space invasion.